Last reviewed · How we verify

Viltepso — Competitive Intelligence Brief

Viltepso (VILTOLARSEN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Rare Disease.

marketed exon 53 of dystrophin pre-mRNA Rare Disease Oligonucleotide Live · refreshed every 30 min

Target snapshot

Viltepso (VILTOLARSEN) — Nippon Shinyaku. Viltepso works by binding to exon 53 of dystrophin pre-mRNA, allowing for the production of a partially functional dystrophin protein.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Viltepso TARGET VILTOLARSEN Nippon Shinyaku marketed exon 53 of dystrophin pre-mRNA 2020-01-01
Amondys 45 CASIMERSEN Sarepta marketed Antisense Oligonucleotide [EPC] exon 53 of dystrophin pre-mRNA 2021-01-01
Vyondys 53 GOLODIRSEN Sarepta marketed Antisense Oligonucleotide [EPC] exon 53 of dystrophin pre-mRNA 2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Viltepso — Competitive Intelligence Brief. https://druglandscape.com/ci/viltolarsen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: